Nitric oxide pathway activation and impaired red blood cell deformability with hypercholesterolemia

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 6, 2006, Pages 286-294

  Kuwai, Taro ^a   Hayashi, Junichi ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

ADMA; Arginine; NO donor; NO synthase inhibitor

Indexed keywords

8 BROMO CYCLIC GMP; 8-BROMOCYCLIC GMP; ARGININE; CYCLIC GMP; DIMETHYLARGININE; DRUG DERIVATIVE; ENZYME INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE;

ANIMAL; ARTICLE; BLOOD; BLOOD ANALYSIS; DRUG ANTAGONISM; DRUG EFFECT; ERYTHROCYTE; FEMALE; HYPERCHOLESTEROLEMIA; METABOLISM; PATHOLOGY; RABBIT;

ANIMALS; ARGININE; BLOOD CHEMICAL ANALYSIS; CYCLIC GMP; ENZYME INHIBITORS; ERYTHROCYTES; FEMALE; HYPERCHOLESTEROLEMIA; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; RABBITS;

EID: 39049195519     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.286     Document Type: Article

References (59)

1. Marin J and Rodriguez-Martinez MA: Role of vascular nitric oxide in physiological and pathological conditions. Pharmacol Ther, 1997; 75:111-134
2. Schmidt HH and Walter U: NO at work. Cell, 1994; 78:919-925
3. Lloyd-Jones DM and Bloch KD: The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med, 1996; 47:365-375
4. Cooke JP and Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med, 1997; 48:489-509
5. Radomski MW, Palmer RM, and Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet, 1987; 2:1057-1058
6. Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, Tsao PS, and Cooke JP: Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol, 1997; 29:479-485
7. Kubes P, Suzuki M, and Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A, 1991; 88:4651-4655
8. Theilmeier G, Chan JR, Zalpour C, Anderson B, Wang BY, Wolf A, Tsao PS, and Cooke JP: Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol, 1997; 17:3557-3564
9. Celermajer DS, Sorensen KE, Bull C, Robinson J, and Deanfield JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol, 1994; 24: 1468-1474
10. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, and Cannon RO 3rd: Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest, 1995; 95:1747-1755
11. Shimokawa H: Endothelial dysfunction in hypertension. J Atheroscler Thromb, 1998; 4:118-127
12. Boger RH, Bode-Boger SM, Szuba A, et al: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998; 98:1842-1847
13. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, and Imaizumi T: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation, 1999; 99:1141-1146
14. Creager MA, Cooke JP, Mendelsohn ME, et al: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest, 1990; 86:228-234
15. Vaya A, Lopez JM, Contreras MT, Falco C, Arguedas J, Corella D, and Aznar J: Erythrocyte deformability in survivors of acute myocardial infarction measured by two different methodologies. Clin Hemorheol Microcirc, 2002; 27:17-25
16. Szapary L, Horvath B, Marton Z, Alexy T, Demeter N, Szots M, Klabuzai A, Kesmarky G, Junicskay I, Gaal V, Czopf J, and Toth K: Hemorheological disturbances in patients with chronic cerebrovascular diseases. Clin Hemorheol Microcirc, 2004; 31:1-9
17. Koksal C, Ercan M, and Bozkurt AK: Hemorrheological variables in critical limb ischemia. Int Angiol, 2002; 21:355-359
18. Bor-Kucukatay M, Wenby RB, Meiselman HJ, and Baskurt OK: Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol, 2003; 284:H1577-1584
19. Butler AR, Megson IL, and Wright PG: Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta, 1998; 1425:168-176
20. Chen LY and Mehta JL: Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function. J Cardiovasc Pharmacol, 1998; 32:57-61
21. Jubelin BC and Gierman JL: Erythrocytes may synthesize their own nitric oxide. Am J Hypertens, 1996; 9:1214-1219
22. Tsuda K and Nishio I: An association between plasma asymmetric dimethylarginine and membrane fluidity of erythrocytes in hypertensive and normotensive men: an electron paramagnetic resonance investigation. Am J Hypertens, 2005; 18:1243-1248
23. Boger RH: Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med, 2005; 10 Suppl 1:S19-25
24. Boger RH: Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med, 2006; 38:126-136
25. Cooke JP: Asymmetrical dimethylarginine: the Uber marker? Circulation, 2004; 109:1813-1818
26. Vallance P and Leiper J: Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethyl-aminohydrolase pathway. Arterioscler Thromb Vasc Biol, 2004; 24:1023-1030
27. Kang ES, Cates TB, Harper DN, Chiang TM, Myers LK, Acchiardo SR, and Kimono M: An enzyme hydrolyzing methylated inhibitors of nitric oxide synthase is present in circulating human red blood cells. Free Radic Res, 2001; 35:693-707
28. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, and Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol, 2001; 88:1201-1203
29. Calver A, Collier J, Leone A, Moncada S, and Valiance P: Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens, 1993; 7:193-194
30. Korbut R and Gryglewski RJ: Nitric oxide from polymorphonuclear leukocytes modulates red blood cell deformability in vitro. Eur J Pharmacol, 1993; 234:17-22
31. Palinski W, Torsellini A, and Doni L: Influence of platelet activation of erythrocyte deformability. Thromb Haemost, 1983; 49:84-86
32. Fetih G, Habib F, Okada N, Fujita T, Attia M, and Yamamoto A: Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu(1,7)]-eel calcitonin in rats. J Control Release, 2005; 106:287-297
33. Garg UC and Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest, 1989; 83:1774-1777
34. Choi J and Farley JM: Effects of 8-bromo-cyclic GMP on membrane potential of single swine tracheal smooth muscle cells. J Pharmacol Exp Ther, 1998; 285:588-594
35. Hayashi J, Ishida N, Sato H, Hata Y, and Saito T: Effect of beraprost, a stable prostacyclin analogue, on red blood cell deformability impairment in the presence of hypercholesterolemia in rabbits. J Cardiovasc Pharmacol, 1996; 27:527-531
36. Starzyk D, Korbut R, and Gryglewski RJ: Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro. J Physiol Pharmacol, 1999; 50:629-637
37. Bor-Kucukatay M, Yalcin O, Gokalp O, Kipmen-Korgun D, Yesilkaya A, Baykal A, Ispir M, Senturk UK, Kaputlu I, and Baskurt OK: Red blood cell rheological alterations in hypertension induced by chronic inhibition of nitric oxide synthesis in rats. Clin Hemorheol Microcirc, 2000; 22:267-275
38. Mesquita R, Pires I, Saldanha C, and Martins-Silva J: Effects of acetylcholine and spermineNONOate on erythrocyte hemorheologic and oxygen carrying properties. Clin Hemorheol Microcirc, 2001; 25:153-163
39. Lee CY, Kim KC, Park HW, Song JH, and Lee CH: Rheological properties of erythrocytes from male hypercholesterolemia. Microvasc Res, 2004; 67:133-138
40. Kamada H, Hattori K, Hayashi T, and Suzuki K: In vitro evaluation of blood coagulation activation and microthrombus formation by a microchannel array flow analyzer. Thromb Res, 2004; 114:195-203
41. Begum AN and Terao J: Protective effect of quercetin against cigarette tar extract-induced impairment of erythrocyte deformability. J Nutr Biochem, 2002; 13:265-272
42. Kurihara T, Deguchi S, Kato J, Furakawa M, Tsuchiya M, Akimoto M, Ishiguro H, Hashimoto H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Kawakami A, Umemura K, Nakashima M, Nakano T, and Saniabadi AR: Impaired blood rheology by remnant-like lipoprotein particles: studies in patients with fatty liver disease. Clin Hemorheol Microcirc, 2001; 24:217-225
43. Chien S: Red cell deformability and its relevance to blood flow. Annu Rev Physiol, 1987; 49:177-192
44. Parthasarathi K and Lipowsky HH: Capillary recruitment in response to tissue hypoxia and its dependence on red blood cell deformability. Am J Physiol, 1999; 277:H2145-2157
45. Kanakaraj P and Singh M: Influence of hypercholesterolemia on morphological and theological characteristics of erythrocytes. Atherosclerosis, 1989; 76:209-218
46. Sheetz MP: Membrane skeletal dynamics: role in modulation of red cell deformability, mobility of transmembrane proteins, and shape. Semin Hematol, 1983; 20:175-188
47. Kensey KR: The mechanistic relationships between hemorheological characteristics and cardiovascular disease. Curr Med Res Opin, 2003; 19:587-596
48. Nash GB and Gratzer WB: Structural determinants of the rigidity of the red cell membrane. Biorheology, 1993; 30:397-407
49. Cooper RA: Abnormalities of cell-membrane fluidity in the pathogenesis of disease. N Engl J Med, 1977; 297:371-377
50. Han TH, Pelling A, Jeon TJ, Gimzewski JK, and Liao JC: Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier. Biochim Biophys Acta, 2005; 1723:135-142
51. Su Y, Kondrikov D, and Block ER: Cytoskeletal regulation of nitric oxide synthase. Cell Biochem Biophys, 2005; 43:439-449
52. Tsuda K, Kimura K, Nishio I, and Masuyama Y: Nitric oxide improves membrane fluidity of erythrocytes in essential hypertension: An electron paramagnetic resonance investigation. Biochem Biophys Res Commun, 2000; 275: 946-954
53. May JM, Qu ZC, Xia L, and Cobb CE: Nitrite uptake and metabolism and oxidant stress in human erythrocytes. Am J Physiol Cell Physiol, 2001; 279:C1946-1954
54. Bogle RG, MacAllister RJ, Whitley GS, and Vallance P: Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol, 1995; 269:C750-756
55. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, and Bode-Boger SM: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylme-thionine-dependent methyltransferases. Circ Res, 2000; 87:99-105
56. Boger RH and Ron ES: L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev, 2005; 10:14-23
57. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, and Cooke JP: L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest, 1992; 90:1248-1253
58. Brandes RP, Brandes S, Boger RH, Bode-Boger SM, and Mugge A: L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix. Life Sci, 2000; 66:1519-1524
59. Tsao PS, Theilmeier G, Singer AH, Leung LL, and Cooke JP: L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb, 1994; 14:1529-1533